Supplementary Information (SI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2024

Supplementary information

Synthesis of benzosultams via Ag(I)-catalyzed alkylative cyclization of vinyl sulfonamides

Raju Dupud, Karthik Kumar Merugu, Remyachand R, and Remya Ramesh* E-mail: r.remya@iict.res.in

Table of Contents

1. General information	S2
2. List of starting materials	S2
3. Synthesis of starting materials	S3
4. Synthesis of benzo-fused-γ-sultams	S6
5. Crystal structure details	S14
6. Copies of NMR spectra	S16

1. General information

All the reactions were performed in oven-dried glass apparatus, the air and moisture sensitive reactions were carried out under inert atmosphere (nitrogen) using freshly distilled anhydrous solvents. Commercially available reagents were used as such without further purification. All reactions were monitored by thin-layer chromatography carried out on silica plates using UV-light and anisaldehyde for visualization. Column chromatography was performed on silica gel (100-200 mesh) using hexanes and ethyl acetate as eluent. NMR spectra were recorded on 400, 500, and 600 MHz spectrometers. δ 7.26 and δ 77 ppm are corresponding to CDCl₃ in ¹H NMR and ¹³C NMR respectively, δ 1.56 ppm is related to moisture present in CDCl₃. Chemical shifts were reported in δ (ppm) relative to TMS as an internal standard and J values are given in Hz (hertz). Multiplicity is indicated as, s (singlet); d (doublet); t (triplet); m (multiplet); dd (doublet of doublets), etc. High resolution mass spectra (HRMS) [ESI+] were obtained using either a TOF or a double focusing spectrometer. Melting point of all solid compounds was determined using a melting point apparatus.

2. List of starting materials

3. Synthesis of starting materials

3.1. General procedure


Step-I: To a solution of aniline (1 equiv.) in dry MeOH was added NaOMe (4 equiv.), followed by paraformaldehyde (4 equiv.) and stirred for 14 h. Then added NaBH₄ (4 equiv.) and heated the reaction mixture at 80 °C for one hour. The reaction mixture was then concentrated under reduced vacuum. Water (15 mL) was added to the reaction mixture, and the aqueous layer was extracted with ethyl acetate (2 x 25 mL). The combined organic layer was dried over anhydrous Na₂SO₄, concentrated in vacuo, and purified by column chromatography using hexane and ethyl acetate.

Step-II: DMAP (0.05 equiv.) was added to a stirring solution of *N*-Methyl aniline (1.0 equiv.) and Triethylamine (3.0 equiv.) in DCM, followed by addition of 2-Chloroethylsulfonyl chloride (1.5 equiv.) at 0 °C dropwise, and then the resulting mixture was stirred for 2-3 h under nitrogen atmosphere. After the reaction was completed (monitored by TLC), The reaction mixture was concentrated under reduced pressure and purified by column chromatography.

3.2. Characterization data

N-methyl-*N*-phenylethenesulfonamide (1a): Compound 1a was prepared according to the general procedure and spectral data matched with the literature reports¹.

N-(3,5-dimethylphenyl)-N-methylethenesulfonamide (1b): yellow oil (383 mg, 93% yield in step II); R_f = 0.4 (Hexane: Ethyl Acetate = 8:2).



¹H NMR (400 MHz, CDCl₃) δ 6.92 (s, 3H), 6.47 (dd, J = 16.6, 9.9 Hz, 1H), 6.21 (d, J = 16.6 Hz, 1H), 6.01 (d, J = 9.9 Hz, 1H), 3.20 (s, 3H), 2.31 (s, 6H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 141.1, 138.9, 132.5, 129.3, 128.1, 124.4, 38.3, 21.3; HRMS (ESI): m/z calcd for C₁₁H₁₅NO₂S [M+H]⁺: 225.0823, found: 225.0793.

Methyl 4-(*N*-methylvinylsulfonamido)benzoate (1c): yellow solid (395 mg, 73% yield in step II), m.p: 64-66 °C; $R_f = 0.5$ (Hexane: Ethyl Acetate = 8:2).

¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 8.7 Hz, 2H), 7.40 (d, J = 8.7 Hz, 2H), 6.43 (dd, J = 16.6, 9.9 Hz, 1H), 6.21 (d, J = 16.6 Hz, 1H), 6.04 (d, J = 9.9 Hz, 1H), 3.92 (s, 3H), 3.28 (s, 3H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 166.3, 145.3, 132.2, 130.5, 129.0, 128.5, 125.3, 52.3, 37.6; HRMS (ESI): m/z calcd for C₁₁H₁₄NO₄S [M+H]⁺: 256.0644,

found: 256.0635.

N-(4-fluorophenyl)-N-methylethenesulfonamide (1d): Dark yellow oil (344 mg, 66% yield in step II); $R_f = 0.4$ (Hexane: Ethyl Acetate = 8:2).

¹H NMR (400 MHz, CDCl₃) δ 7.32 – 7.27 (m, 2H), 7.10 – 7.00 (m, 2H), 6.45 (dd, J = 16.6, 9.9 Hz, 1H), 6.19 (d, J = 16.6 Hz, 1H), 6.03 (d, J = 9.9 Hz, 1H), 3.22 (s, 3H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 161.6 (d, J = 247.6 Hz), 137.1 (d, J = 2.7 Hz), 132.1, 128.8, 128.6 (d, J = 8.6 Hz), 116.1 (d, J = 22.7 Hz), 38.3; ¹⁹F NMR

(376 MHz, CDCl3) δ -113.7; HRMS (ESI): m/z calcd for C₉H₁₁NO₂SF [M+H]⁺ : 216.0495, found: 216.0494.

N-(**2-iodophenyl**)-*N*-methylethenesulfonamide (**1e**): Black Solid (301 mg, 93% yield in step II); m.p: 60-62 °C; $R_f = 0.6$ (Hexane: Ethyl Acetate = 8:2).

¹H NMR (400 MHz, CDCl₃) δ 7.93 – 7.90 (m, 1H), 7.38 (dd, J = 5.3, 2.1 Hz, 2H), 7.08 – 7.03 (m, 1H), 6.71 (dd, J = 16.5, 9.9 Hz, 1H), 6.27 (d, J = 16.5 Hz, 1H), 6.05 (d, J = 9.9 Hz, 1H), 3.16 (s, 3H); ¹³C{¹H}NMR (75 MHz, CDCl₃) δ 143.2, 140.3, 134.9, 130.2, 129.9, 129.5, 128.1, 101.3, 38.2;

HRMS (ESI): *m/z* calcd for C₉H₁₁NO₂SI [M+H]⁺:323.9555 found: 323.9531.

N-([1,1'-biphenyl]-2-yl)-N-methylethenesulfonamide (1f): Brown oil (407 mg, 91% yield in step II), R_f = 0.5(Hexane: Ethyl Acetate = 8:2).

¹H NMR (400 MHz, CDCl₃) δ 7.44 (d, J = 4.5 Hz, 4H), 7.41 – 7.36 (m, 5H), 6.19 – 6.06 (m, 2H), 5.87 (dd, J = 8.6, 1.1 Hz, 1H), 2.97 (s, 3H); ¹³C{¹H}NMR (101 MHz, CDCl₃) δ 142.1, 139.3, 139.0, 134.6, 131.4, 129.2, 128.5, 128.4, 128.2, 127.5, 127.4, 38.6.; HRMS (ESI): m/z calcd for C₁₅H₁₅NO₂NaS [M+Na]⁺: 296.0721, found: 296.0667.

N-(2-cyano-[1,1'-biphenyl]-3-yl)-N-methylethenesulfonamide (1g): yellow solid (269 mg, 75% yield in step II), m.p: 106-108°C; R_f = 0.5(Hexane: Ethyl Acetate = 8:2).

¹H NMR (400 MHz, CDCl₃) δ 7.66 (t, J = 7.9 Hz, 1H), 7.56 – 7.45 (m, 7H), 6.76 (dd, J = 16.5, 9.8 Hz, 1H), 6.34 (d, J = 16.5 Hz, 1H), 6.11 (d, J = 9.8 Hz, 1H), 3.34 (s, 3H); ¹³C{¹H}NMR (101 MHz, CDCl₃) δ 147.6, 144.6, 137.5, 136.2, 134.5, 133.3, 129.8, 129.1, 129.0, 128.9, 128.8, 116.3, 112.5, 38.3; HRMS (ESI): m/z calcd for C₁₆H₁₅N₂O₂S [M+H]⁺: 299.0854, found: 299.0852.

N-(2-cyano-4'-methoxy-[1,1'-biphenyl]-3-yl)-N-methylethenesulfonamide (1h): yellow solid (273 mg, 79% yield in step II), m.p: 110-112 °C; R_f = 0.4 (Hexane: Ethyl Acetate = 8:2).

¹H NMR (400 MHz, CDCl₃) δ 7.63 (t, J = 7.9 Hz, 1H), 7.52 - 7.44 (m, 4H), 7.04 - 6.99 (m, 2H), 6.76 (dd, J = 16.5, 9.8 Hz, 1H), 6.34 (d, J = 16.5 Hz, 1H), 6.11 (d, J = 9.8 Hz, 1H), 3.87 (s, 3H), 3.34 (s, 3H); ¹³C{¹H}NMR (101 MHz, CDCl₃) δ 160.4, 147.4, 144.6, 134.5, 133.3, 130.2, 129.8, 129.6, 129.0, 128.4, 116.6, 114.3, 112.2, 55.4, 38.3; HRMS (ESI):

m/z calcd for C₁₇H₁₇N₂O₃S [M+H]⁺: 329.096, found: 329.0945.

N-(5-bromopyridin-2-yl)-N-methylethenesulfonamide (1i): yellow oil (394 mg, 83% yield in step II), $R_f = 0.6$ (Hexane: Ethyl Acetate = 7:3).

¹H NMR (400 MHz, CDCl₃) δ 8.43 (dd, J = 2.5, 0.5 Hz, 1H), 7.79 (dd, J = 8.7, 2.5 Hz, 1H), 7.43 (dd, J = 8.7, 0.7 Hz, 1H), 6.49 (dd, J = 16.6, 9.9 Hz, 1H), 6.27 (d, J = 16.6 Hz, 1H), 6.04 (d, J = 9.9 Hz, 1H), 3.31 (s, 3H); ¹³C{¹H}NMR (126 MHz, CDCl₃) δ 152.3, 149.1, 140.4, 133.0, 128.8, 121.3, 117.5, 35.6; HRMS (ESI): m/z calcd for C₈H₁₀N₂O₂SBr

[M+H]⁺: 276.9646, found: 276.9630.

N-methyl-*N*-(quinolin-6-yl)ethenesulfonamide (1j): yellow oil (221 mg, 70% yield in step II); $R_f = 0.5$ (Hexane: Ethyl Acetate = 7:3).

¹H NMR (400 MHz, CDCl₃) δ 8.93 (dd, J = 4.2, 1.7 Hz, 1H), 8.19 – 8.07 (m, 2H), 7.78 (d, J = 2.4 Hz, 1H), 7.70 (dd, J = 9.0, 2.5 Hz, 1H), 7.44 (dd, J = 8.3, 4.2 Hz, 1H), 6.49 (dd, J = 16.6, 9.9 Hz, 1H), 6.23 (d, J = 16.6 Hz, 1H), 6.05 (d, J = 9.9 Hz, 1H), 3.36 (s, 3H); ¹³C{¹H}

NMR (126 MHz, CDCl₃) δ 150.9, 146.9, 139.2, 136.1, 132.2, 130.6, 129.0, 128.2, 128.0, 124.7, 121.8, 38.1.; HRMS (ESI): m/z calcd for $C_{12}H_{13}N_2O_2S$ [M+H]⁺: 249.0698, found: 249.0691.

N-ethyl-*N*-phenylethenesulfonamide (1k):(Commercial available N-ethyl aniline is subjected to step-II) pale yellow oil (311 mg, 79% yield in step II); $R_f = 0.5$ (Hexane: Ethyl Acetate = 8:2).

¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.27 (m, 5H), 6.54 (dd, J = 16.6, 9.9 Hz, 1H), 6.15 (d, J = 16.6 Hz, 1H), 5.94 (d, J = 9.9 Hz, 1H), 3.65 (q, J = 7.1 Hz, 2H), 1.13 (t, J = 7.1 Hz, 3H); ¹³C{¹H}NMR (101 MHz, CDCl₃) δ 138.7, 134.1, 129.3, 129.0, 128.1, 127.3, 45.9, 14.4; HRMS (ESI): m/z calcd for C₁₀H₁₄NO₂S[M+H]⁺: 212.0745, found: 212.0766.

4. Synthesis of benzo-fused-γ-sultams:


4.1. General procedure

N-phenyl Sulfonamide (0.253 mmol, 1 equiv.), Sodium per sulphate (1.27 mmol, 5 equiv.), and Silver carbonate (0.025 mmol, 0.1 equiv.) and pivalic acid (0.761 mmol, 3 equiv.) were taken

in a reaction vial, and 3-mL of CH₃CN:H₂O (1:1) was added. The reaction mixture was stirred at 85°C (oil bath temperature) for 2h. After completion of the reaction (monitored by TLC), the reaction was quenched with cold water (5 mL) and extracted with ethyl acetate (10 mL X 3). The combined organic extracts were dried over Na₂SO₄, and the solvent was removed under reduced pressure. The crude reaction mixture was then purified by column chromatography on silica gel (100-200) using ethyl acetate and hexane as an eluent to afford the desired product.

4.2. Characterization data


1-methyl-3-neopentyl-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide** (3a): Brown oil (57 mg, 88% yield); $R_f = 0.7$ (Hexane: Ethyl acetate = 8:2).



¹H NMR (400 MHz, CDCl₃) δ 7.30 (t, J = 7.8 Hz, 1H), 7.18 (d, J = 7.6 Hz, 1H), 7.01 (td, J = 7.6, 0.9 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 4.30 – 4.14 (m, 1H), 3.13 (s, 3H), 2.38 (dd, J = 15.6, 7.6 Hz, 1H), 1.83 (dd, J = 15.6, 2.5

Hz, 1H), 1.12 (s, 9H); ${}^{13}C\{{}^{1}H\}$ NMR (101 MHz, CDCl₃) δ 141.0, 129.2, 124.3, 124.2, 121.8, 108.8, 57.9, 42.4, 30.5, 29.4, 26.8; HRMS (ESI): m/z calcd for $C_{17}H_{19}NO_{2}NaS$ [M+Na]⁺: 276.1034, found: 276.1022.

1,4,6-trimethyl-3-neopentyl-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide** (**3b**): White solid (56 mg, 91% yield); m.p: 102-104 °C; $R_f = 0.6$ (Hexane: Ethyl acetate = 8:2).



¹H NMR (300 MHz, CDCl₃) δ 6.64 (s, 1H), 6.35 (s, 1H), 4.16 (d, J = 9.1 Hz, 1H), 3.08 (s, 3H), 2.31 (s, 3H), 2.27 (s, 3H), 2.23 (d, J = 9.2 Hz, 1H), 1.53 (dd, J = 15.7, 0.6 Hz, 1H), 1.11 (s, 9H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 140.4, 139.2, 134.1, 124.8, 120.5, 107.5, 57.9, 43.4, 31.2, 29.6, 26.8, 21.6, 19.2; HRMS (ESI): m/z calcd for C₁₅H₂₄NO₂S [M+H]⁺:


282.1528, found: 282.1553.

Methyl 1-methyl-3-neopentyl-1,3-dihydrobenzo[c]isothiazole-5-carboxylate 2,2-dioxide (3c): white solid (42 mg, 69 % yield); m.p: 78-80 °C; $R_f = 0.6$ (Hexane: Ethyl Acetate = 8:2).

¹H NMR (500 MHz, CDCl₃) δ 8.05 – 8.01 (m, 1H), 7.85 (s, 1H), 6.70 (d, J = 8.4 Hz, 1H), 4.25 (d, J = 8.1 Hz, 1H), 3.91 (s, 3H), 3.19 (s, 3H), 2.38 (dd, J = 15.6, 8.2 Hz, 1H), 1.91 (dd, J = 15.6, 2.1 Hz, 1H), 1.14 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 166.3, 144.5, 131.6, 125.8,

123.8, 123.6, 108.0, 57.8, 52.2, 42.5, 30.5, 29.4, 26.7; HRMS (ESI): m/z calcd for $C_{15}H_{14}NO_4S$ [M+H]⁺: 312.1270, found: 312.1292.


5-fluoro-1-methyl-3-neopentyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (3d): yellow Solid (50 mg, 79% yield; m.p. 85-87 °C; $R_f = 0.8$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (400 MHz, CDCl₃) δ 7.04 – 6.98 (m, 1H), 6.97 – 6.93 (m, 1H), 6.63 (dd, J = 8.7, 4.3 Hz, 1H), 4.22 – 4.16 (m, 1H), 3.12 (s, 3H), 2.38 (dd, J = 15.6, 7.5 Hz, 1H), 1.77 (dd, J = 15.6, 2.6 Hz, 1H), 1.12 (s, 9H); 13 C{ 1 H}NMR (126 MHz, CDCl₃) 158.1 (d, J = 241.2 Hz),137.2, 125.8 (d,

J = 8.2 Hz), 115.7 (d, J = 23.1 Hz), 112.2 (d, J = 25.4 Hz), 109.9 (d, J = 8.0 Hz), 58.1, 42.3, 30.5, 29.4, 27.2; ¹⁹F NMR (377 MHz, CDCl₃) δ -120.3; HRMS (ESI): m/z calcd for C₁₃H₁₉NO₂FS [M+H]⁺: 272.1121, found: 272.1113.


7-iodo-1-methyl-3-neopentyl-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide** (**3e**): Yellow solid (44 mg, 74% yield); m.p. 83-85 °C; R_f = 0.8 (Hexane: Ethyl Acetate = 8:2).



¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 6.90 (t, J = 7.8 Hz, 1H), 4.20 (dd, J = 7.5, 2.4 Hz, 1H), 3.37 (s, 3H), 2.30 (dd, J = 15.3, 7.6 Hz, 1H), 1.70 (dd, J = 15.3, 2.6 Hz, 1H), 1.11 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃)

 δ 144.6, 140.4, 132.3, 126.6, 124.7, 83.7, 59.3, 44.1, 37.5, 30.7, 29.4; HRMS (ESI): m/z calcd for C₁₃H₁₉NO₂SI [M+H]⁺: 380.0181 found: 380.0187.


1-methyl-3-neopentyl-7-phenyl-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide** (3f): yellow solid (42 mg, 68% yield); m.p. 84- 85 °C; $R_f = 0.6$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (300 MHz, CDCl₃) δ 7.46 – 7.41 (m, 2H), 7.40 – 7.29 (m, 3H), 7.22 – 7.16 (m, 1H), 7.14 – 7.09 (m, 2H), 4.13 (dd, J = 7.7, 2.2 Hz, 1H), 2.62 (s, 3H), 2.29 (dd, J = 15.4, 7.7 Hz, 1H), 1.71 (dd, J = 15.4, 2.3 Hz, 1H), 1.06 (s, 9H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 139.6, 138.0, 131.3, 129.6, 129.5, 128.7, 128.6, 127.9, 124.1, 123.6, 58.3, 44.4, 35.0, 30.7, 29.4; HRMS (ESI): m/z calcd for C₁₉H₂₃NO₂NaS [M+Na]⁺: 352.1347, found:

352.1339.

1-methyl-3-neopentyl-6-phenyl-1,3-dihydrobenzo[c]isothiazole-7-carbonitrile 2,2-dioxide (3g): yellow solid (43 mg, 72% yield); m.p: 136-138 °C; $R_f = 0.6$ (Hexane: Ethyl Acetate = 8:2).




¹H NMR (300 MHz, CDCl₃) δ 7.48 (s, 5H), 7.38 (dd, J = 7.9, 0.7 Hz, 1H), 7.08 (d, J = 7.9 Hz, 1H), 4.19 (d, J = 7.2 Hz, 1H), 3.61 (s, 3H), 2.41 (dd, J = 15.5, 7.9 Hz, 1H), 1.80 (dd, J = 15.5, 2.2 Hz, 1H), 1.14 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 147.7, 143.6, 137.8, 129.1, 128.9, 128.7, 128.3, 125.2, 123.2, 116.2, 94.7, 56.7, 43.2, 30.7,

30.0, 29.4; HRMS (ESI): m/z calcd for $C_{20}H_{23}N_2O_2S$ [M+H]⁺: 355.148, found: 355.1466.

$6\hbox{-}(4\hbox{-methoxyphenyl})\hbox{-}1\hbox{-methyl-}3\hbox{-neopentyl-}1, 3\hbox{-dihydrobenzo} [c] is othiz zole-7-$


carbonitrile 2,2-dioxide (3h): yellow solid (44mg, 75% yield); m.p: 188-190 °C; $R_f = 0.5$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (300 MHz, CDCl₃) δ 7.45 (d, J = 8.8 Hz, 2H), 7.37 (dd, J = 7.9, 1.0 Hz, 1H), 7.08 (d, J = 7.9 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 4.20 (d, J = 7.0 Hz, 1H), 3.89 (s, 3H), 3.63 (s, 3H), 2.42 (dd, J = 15.5, 7.9 Hz, 1H), 1.81 (dd, J = 15.5, 2.2 Hz, 1H), 1.16 (s,

9H); 13 C { 1 H} NMR (101 MHz, CDCl₃) δ 148.5, 144.6, 138.7, 130.0, 129.8, 129.6, 129.3, 126.4, 124.1, 117.1, 95.5, 55.9, 44.9, 43.0, 37.6, 33.2, 30.9; HRMS (ESI): m/z calcd for $C_{21}H_{25}N_2O_3S$ [M+H] $^+$: 385.1586, found: 385.1579.


5-bromo-1-methyl-3-neopentyl-1,3-dihydroisothiazolo[3,4-*b***] pyridine 2,2-dioxide (3i):** pale-yellow solid (43 mg, 71% yield); m.p: 113-115 °C; $R_f = 0.7$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (300 MHz, CDCl₃) δ 8.23 (s, 1H), 7.52 – 7.48 (m, 1H), 4.27 (d, J = 7.9 Hz, 1H), 3.24 (s, 3H), 2.41 (dd, J = 15.6, 7.9 Hz, 1H), 1.76 (dd, J = 15.6, 2.4 Hz, 1H), 1.12 (s, 9H); ¹³C{¹H}NMR (126 MHz, CDCl₃) ¹³C NMR (126 MHz, CDCl₃) δ 151.1, 148.7, 134.6, 120.8, 112.1, 58.2, 42.4,

30.5, 29.3, 25.4; HRMS (ESI): m/z calcd for $C_{12}H_{18}N_2O_2SBr$ [M+H]⁺: 333.0272, found: 333.0265.

3-methyl-1-neopentyl-1,3-dihydroisothiazolo[4,3-f]quinoline 2,2-dioxide (3j): yellow solid (38 mg, 63% yield); m.p: 170-172 °C; $R_f = 0.2$ (Hexane: Ethyl Acetate = 7:3).



¹H NMR (300 MHz, CDCl₃) δ 8.84 (dd, J = 4.2, 1.5 Hz, 1H), 8.10 (d, J = 9.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.45 (dd, J = 8.6, 4.2 Hz, 1H), 7.24 (d, J = 4.5 Hz, 1H), 4.62 (d, J = 9.2 Hz, 1H), 3.27 (s, 3H), 2.36 (dd, J = 15.8, 9.3 Hz, 1H), 1.71 (d, J = 15.7 Hz, 1H), 1.22 (s, 9H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 148.4, 144.8, 138.5, 132.1, 129.9, 124.5, 122.3, 116.2, 113.8,


58.1, 44.0, 31.4, 29.7, 27.7; HRMS (ESI): m/z calcd for $C_{16}H_{21}N_2O_2S$ [M+H]⁺: 305.1323, found: 305.0319.

1-ethyl-3-neopentyl-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide** (3k): yellow solid (56 mg, 85% yield); m.p. 80-82 °C; $R_f = 0.7$ (Hexane: Ethyl Acetate = 8:2).

¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.26 (m, 1H), 7.17 (d, J = 7.6 Hz, 1H), 6.99 (td, J = 7.6, 0.8 Hz, 1H), 6.71 (d, J = 8.0 Hz, 1H), 4.18 (d, J = 7.6 Hz, 1H), 3.70 (qd, J = 7.3, 3.6 Hz, 2H), 2.38 (dd, J = 15.5, 7.7 Hz, 1H), 1.80 (dd, J = 15.5, 2.3 Hz, 1H), 1.39 (t, J = 7.2 Hz, 3H), 1.12 (s, 9H);

 13 C{ 1 H} NMR (101 MHz, CDCl₃) δ 139.8, 129.1, 124.5, 124.3, 121.4, 108.8, 58.3, 42.8, 36.6, 30.5, 29.4, 13.4; HRMS (ESI): m/z calcd for C₁₄H₂₁NO₂NaS [M+H]⁺: 290.1191, found: 290.1175.

1-methyl-3-(2-methylbutyl)-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide** (**3l**): yellow oil (55 mg, 86% yield); $R_f = 0.7$ (Hexane: Ethyl Acetate = 8:2). (Mixture of diastereomers)




¹H NMR (400 MHz, CDCl₃) δ 7.31 (t, J = 7.8 Hz, 1H), 7.19 (t, J = 8.3 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 6.71 (dd, J = 7.9, 4.3 Hz, 1H), 4.31 (dd, J = 10.0, 4.9 Hz, 1H), 3.12 (s, 3H), 2.23 – 2.14 (m, 1H), 1.89 – 1.80 (m, 1H), 1.77 – 1.69 (m, 1H), 1.56 – 1.45 (m, 1H), 1.36 – 1.24 (m, 1H), 1.07 (d, J = 2.8 Hz, 3H), 0.99 – 0.90 (m, 3H); ¹³C{¹H}

NMR (75 MHz, CDCl₃) δ 141.0, 129.3, 124.7, 123.4, 121.8, 109.1, 58.6, 36.2, 31.8, 29.8, 26.5, 19.1, 11.1; ¹H NMR (400 MHz, CDCl₃) δ 7.31 (t, J = 7.8 Hz, 1H), 7.19 (t, J = 8.3 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 6.71 (dd, J = 7.9, 4.3 Hz, 1H), 4.26 (t, J = 7.1 Hz, 1H), 3.12 (s, 3H), 2.05 – 1.97 (m, 1H), 1.89 – 1.80 (m, 1H), 1.56 – 1.45 (m, 1H), 1.36 – 1.24 (m, 2H), 1.06 (d, J = 2.6 Hz, 3H), 0.99 – 0.90 (m, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 140.9, 129.2, 124.3, 123.4, 121.8, 109.0, 58.6, 35.9, 31.5, 28.8, 26.4, 18.7, 11.0; HRMS (ESI): m/z calcd for C₁₃H₁₉NO₂NaS [M+Na]+: 276.1034, found: 276.1022.

3-dodecyl-1-methyl-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide** (3m): yellow liquid (67 mg, 75% yield); $R_f = 0.6$ (Hexane: Ethyl Acetate = 8:2).


¹H NMR (400 MHz, CDCl₃) δ 7.31 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 7.5 Hz, 1H), 7.00 (dd, J =



11.0, 4.2 Hz, 1H), 6.71 (d, J = 7.9 Hz, 1H), 4.17 (dd, J = 8.4, 6.0 Hz, 1H), 3.12 (s, 3H), 2.17 – 2.06 (m, 1H), 2.02 – 1.92 (m, 1H), 1.73 – 1.60 (m, 3H), 1.45 – 1.37 (m, 3H), 1.35 – 1.21 (m, 14H), 0.88 (t, J = 6.8 Hz, 3H); 13 C{ 1 H} NMR (101 MHz, CDCl₃) δ 140.9, 129.3, 124.6, 123.1, 121.8, 109.0, 60.7, 31.8, 29.7, 29.4, 29.3, 29.2, 29.2, 26.6,

26.5, 22.7, 14.1.; HRMS (ESI): m/z calcd for $C_{20}H_{34}NO_2S$ [M+H]+: 352.2310, found: 352.2304.


3-(6-chlorohexyl)-1-methyl-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide** (**3n**): yellow oil(56 mg, 74% yield); $R_f = 0.8$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (400 MHz, CDCl₃) δ 7.32 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 7.5 Hz, 1H), 7.01 (t, J = 7.1 Hz, 1H), 6.71 (d, J = 7.9 Hz, 1H), 4.17 (dd, J = 8.7, 5.6 Hz, 1H), 3.54 (t, J = 6.7 Hz, 2H), 3.12 (s, 3H), 2.17 – 2.07 (m, 1H), 2.05 – 1.96 (m, 1H), 1.83 – 1.76 (m, 2H), 1.73 – 1.65 (m, 2H), 1.54 – 1.43 (m, 4H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 140.9, 129.4, 124., 122.9, 121.8, 109.1, 60.7, 45.0, 32.4, 29.2, 28.7, 26.6, 26.5, 26.4; HRMS

(ESI): *m/z* calcd for C₁₄H₂₀ClNO₂NaS [M+Na]⁺: 324.0801, found: 324.0792.


3-(cyclobutylmethyl)-1-methyl-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide** (**30):** yellow oil (46 mg, 73% yield); $R_f = 0.7$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (300 MHz, CDCl₃) δ 7.31 (t, J = 7.8 Hz, 1H), 7.19 (d, J = 7.5 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 6.70 (d, J = 7.9 Hz, 1H), 4.13 – 4.04 (m, 1H), 3.11 (s, 3H), 2.70 (m, 1H), 2.30 – 2.11 (m, 3H), 2.08 – 1.81 (m, 3H), 1.74 (dd, J = 18.2, 9.1 Hz, 2H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 141.0, 129.3, 124.6, 123.0,

121.7, 109.1, 58.9, 36.0, 32.9, 28.3, 28.1, 26.4, 18.2; HRMS (ESI): m/z calcd for $C_{13}H_{17}NO_2NaS$ [M+Na]⁺: 274.0878, found: 274.0865.


1-methyl-3-((1-methylcyclohexyl)methyl)-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (3p): yellow oil(62 mg, 83% yield); $R_f = 0.7$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (400 MHz, CDCl₃) δ 7.29 (t, J = 7.8 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 4.24 (dd, J = 6.3, 1.0 Hz, 1H), 3.13 (s, 3H), 2.41 (dd, J = 15.7, 7.4 Hz, 1H), 1.84 (dd, J = 15.7, 2.5 Hz, 1H), 1.61 – 1.49 (m, 6H), 1.48 – 1.40 (m, 4H), 1.10 (s, 3H); ¹³C{¹H}

NMR (75 MHz, CDCl₃) δ 141.0, 129.2, 124.4, 124.3, 121.8, 108.8, 57.1, 41.4, 37.8, 37.4, 32.8, 26.8, 26.2, 24.4, 22.0, 21.9; HRMS (ESI): m/z calcd for C₁₆H₂₃NO₂NaS [M+Na]⁺: 316.1347, found: 316.1379.


1-methyl-3-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dihydrobenzo[c]isothiazole **2,2-dioxide (3q):** White Solid (59 mg, 82% yield); m.p: 112-114 °C; $R_f = 0.6$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (300 MHz, CDCl₃) δ 7.33 (t, J = 7.8 Hz, 1H), 7.18 (d, J = 7.5 Hz, 1H), 7.02 (t, J = 7.6 Hz, 1H), 6.72 (d, J = 7.9 Hz, 1H), 4.32 (dd, J = 9.6, 5.2 Hz, 1H), 4.05 – 3.97 (m, 2H), 3.46 (td, J = 11.9, 2.2 Hz, 2H), 3.13 (s, 3H), 2.19 – 2.08 (m, 1H), 2.07 – 1.95 (m, 1H), 1.92 – 1.82 (m, 2H), 1.76 (ddd, J = 13.2, 3.6, 2.0 Hz, 1H), 1.50 – 1.32 (m, 2H); ¹³C{¹H}

NMR (75 MHz, CDCl₃) δ 141.0, 129.4, 124.3, 122.9, 121.9, 109.1, 67.7, 57.4, 36.11, 33.3, 32.3, 32.2, 26.5; HRMS (ESI): m/z calcd for C₁₄H₁₉NO₃NaS [M+Na]+: 304.0983, found: 304.0979.


3-(adamantan-1-ylmethyl)-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (3r): yellow solid (68 mg, 81% yield); m.p: 130-132 °C; R_f = 0.3 (hexanes: Ethyl Acetate = 8:2).



¹H NMR (300 MHz, CDCl₃) δ 7.33 – 7.25 (m, 1H), 7.17 (d, J = 7.6 Hz, 1H), 7.00 (t, J = 7.6 Hz, 1H), 6.67 (d, J = 7.9 Hz, 1H), 4.28 (d, J = 7.2 Hz, 1H), 3.13 (s, 3H), 2.26 (dd, J = 15.7, 7.4 Hz, 1H), 2.11 – 2.04 (m, 3H), 1.83 – 1.76 (m, 2H), 1.75 – 1.64 (m, 11H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 141.0, 129.1, 124.5, 124.4, 121.8, 108.7, 56.1, 43.1,

42.1, 38.3, 36.8, 36.6, 32.1, 28.5, 28.0, 26.8; HRMS (ESI): m/z calcd for $C_{19}H_{26}NO_2S$ [M+H]⁺: 332.1684, found: 332.1697.


3-((3,5-dimethyladamantan-1-yl)methyl)-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (3s): White solid (82 mg, 90% yield); m.p: 93-95 °C; $R_f = 0.4$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (400 MHz, CDCl₃) δ 7.29 (t, J = 7.8 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 6.67 (d, J = 7.9 Hz, 1H), 4.27 (d, J = 6.4 Hz, 1H), 3.13 (s, 3H), 2.29 (dd, J = 15.7, 7.5 Hz, 1H), 2.14 (m, 1H), 1.70 (dd, J = 15.7, 2.5 Hz, 1H), 1.51 (s, 2H), 1.36 (s, 4H), 1.34 – 1.29 (m, 2H), 1.25 (dd, J = 12.2, 4.0 Hz, 2H), 1.16 (q, J = 12.4 Hz, 2H), 0.86 (s, 6H); ¹³C{¹H} NMR

 $(75 \text{ MHz}, \text{CDCl}_3) \delta 141.0, 129.1, 124.5, 124.4, 121.8, 108.7, 56.2, 51.0, 48.6, 48.3, 43.0, 42.5, 40.7, 33.9, 31.3, 30.6, 29.6, 26.8; HRMS (ESI): <math>m/z$ calcd for $C_{21}H_{30}NO_2S$ [M+H]⁺: 360.1997, found: 360.2009.


3-((3-hydroxyadamantan-1-yl)methyl)-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (3t): White solid (75 mg, 85% yield); m.p: 138-140 °C; R_f = 0.3 (Hexane: Ethyl Acetate = 8:2).



¹H NMR (400 MHz, CDCl₃) δ 7.30 (t, J = 7.8 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 7.01 (t, J = 7.6, Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 4.26 (d, J = 7.6 Hz, 1H), 3.13 (s, 3H), 2.38 – 2.27 (m, 3H), 1.77 (dd, J = 15.7, 2.4 Hz, 1H), 1.73 – 1.66 (m, 4H), 1.65 – 1.58 (m, 8H); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 141.0, 129.3, 124.3, 124.0, 121.9, 108.8, 68.8, 56.3, 49.8, 44.5, 44.5, 42.2,

41.0, 40.5, 35.8, 35.2, 30.6, 30.5, 26.8; HRMS (ESI): m/z calcd for $C_{19}H_{25}NO_3NaS$ [M+Na]⁺: 370.1453, found: 370.1432.


1-methyl-3-(4-phenylbutyl)-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (3u): Yellow oil (57 mg, 72% yield); $R_f = 0.8$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (500 MHz, CDCl₃) δ 7.33 – 7.26 (m, 3H), 7.21 – 7.17 (m, 3H), 7.14 (d, J = 7.5 Hz, 1H), 7.01 – 6.97 (m, 1H), 6.71 (d, J = 7.9 Hz, 1H), 4.15 (dd, J = 8.6, 5.8 Hz, 1H), 3.12 (s, 3H), 2.66 (t, J = 7.2 Hz, 2H), 2.19 – 2.11 (m, 1H), 2.04 – 1.96 (m, 1H), 1.77 – 1.70 (m, 4H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 142.1, 140.9, 129.4, 128.4, 128.4, 125.9, 124.6,

122.9, 121.8, 109.1, 60.6, 35.6, 31.2, 29.3, 26.5, 26.2; HRMS (ESI): m/z calcd for $C_{18}H_{21}NO_2NaS$ [M+Na]⁺: 338.1191, found: 338.1155.

3-isobutyl-1-methyl-1,3-dihydrobenzo[c]isothiazole 2,2-dioxide (3v): Yellow oil (47 mg, 78% yield); $R_f = 0.8$ (Hexane: Ethyl Acetate = 8:2).



¹H NMR (300 MHz, CDCl₃) δ 7.31 (t, J = 7.8 Hz, 1H), 7.19 (d, J = 7.5 Hz, 1H), 7.00 (t, J = 7.6 Hz, 1H), 6.71 (d, J = 7.9 Hz, 1H), 4.35 – 4.14 (m, 1H), 3.12 (s, 3H), 2.14 – 2.02 (m, 2H), 1.83 – 1.69 (m, 1H), 1.08 (d, J = 6.2 Hz, 6H); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 140.9, 129.3, 124.5, 123.3, 121.8, 109.1, 58.7, 38.0, 26.5, 25.5, 22.8, 22.0; HRMS (ESI): m/z calcd for

 $C_{12}H_{17}NO_2NaS [M+Na]^+$: 262.0878, found: 262.0848.

5. Crystal structure details

X-ray data for the compound was collected on a Bruker D8 QUEST instrument with an I μ S Mo microsource ($\lambda = 0.7107$ A) and a PHOTON-III detector. The raw data frames were reduced and corrected for absorption effects using the Bruker Apex 3 software suite programs.² The structure was solved using intrinsic phasing method and further refined with the SHELXL program and expanded using Fourier techniques.³ Anisotropic displacement parameters were included for all non-hydrogen atoms. All C bound H atoms were positioned geometrically and treated as riding on their parent C atoms [C-H = 0.93-0.97 Å, and Uiso(H) = 1.5Ueq(C) for methyl H or 1.2Ueq(C) for other H atoms]. The carbon atoms C15, C16, C17, C18, and C19 are disordered over two positions, the major and minor occupancy factors were refined to 0.595 (5) and 0.405 (5) respectively.

Compound 3f:

Crystal of compound **3f** was developed in DCM, and X-ray data was collected at low temperature.

Crystal Data for $C_{19}H_{23}NO_2S$ (M =329.44 g/mol): monoclinic, space group P21/c (no.14), a =13.6647(4) Å, b =17.8621(5) Å, c = 7.4013(2) Å, β = 97.8140(10)°, V = 1789.74(9) Å 3 , Z = 4, T = 100.15 K, $\mu(MoK\alpha)$ = 0.190 mm -1 , Dcalc = 1.223 g/cm³, 14932 reflections measured (4.56° \leq 20 \leq 52.666°), 3606 unique (Rint = 0.0644, Rsigma = 0.0719) which were used in all calculations. The final R1 was 0.0771 (I & gt; 2 σ (I)) and wR 2 was 0.1943.


Compound 3g:


Crystal of compound **3g** was developed in Chloroform, and X-ray data was collected at room temperature.


Crystal Data for $C_{20}H_{22}N_2O_2S$ (M = 354.45 g/mol): orthorhombic, space group Pbca (no. 61), a = 14.3600(4) Å, b = 9.5280(3) Å, c = 28.4766(8) Å, V = 3896.2(2) Å 3, Z = 8, T = 14.3600(4) Å, C = 28.4766(8) Å


 $294.15~K,~\mu(MoK\alpha)=0.181~mm^{-1}$, Dcalc = $1.209~g/cm^3,~28438$ reflections measured (5.326° $\leq 2\Theta \leq 56.676^\circ$), 4854 unique (Rint = 0.0532, Rsigma = 0.0479) which were used in all calculations. The final R1 was 0.0689 (I & gt; $2\sigma(I)$) and wR2 was 0.2536.


5. Copies of NMR spectra


































































































































































































References:

- 1) D. Vytla, K. Kaliyaperumal, R. Velayuthaperumal, P. Shaw, R. Gautam, A. Mathur, A. Roy. *Synthesis*, 2022, **54**, 667–682.
- 2) Bruker (2016). APEX3, SAINT and SADABS. Bruker AXS, Inc., Madison, Wisconsin, USA.
- 3) Sheldrick G. M. (2015). ActaCrystallogr. C71: 3-8.